1-3 of 3
Kenneth Y. Tsai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A021: Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma

Free
Kavita Y. Sarin, John Kincaid, Brittney Sell, Jahanbanoo Shahryari, Matthew A. J. Duncton, Elaine Morefield, Wenchao Sun, Omar Chavez-Chiang, Scott R. Plotkin, Gerd G. Kochendoerfer, Peter Fenn, Christopher Powala, Kenneth Y. Tsai
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2022) 15 (12_Supplement_2): A021.
https://doi.org/10.1158/1940-6215.TACPAD22-A021
Published: 01 December 2022
View articletitled, Abstract A021: Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
Journal Articles

Abstract PR08: Noninvasive epidermal sampling as a means of genomic UV dosimetry

Free
Kenneth Y. Tsai, Elnara Muradova, Sandy S. Ojeda, Charles H. Adelmann, Kimberly Nguyen, Samir Mitragotri, Nishit Patel
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2020) 13 (7_Supplement): PR08.
https://doi.org/10.1158/1940-6215.ENVCAPREV19-PR08
Published: 02 July 2020
View articletitled, Abstract PR08: Noninvasive epidermal sampling as a means of genomic UV dosimetry
Journal Articles

When “Effective” Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design

Free
Kenneth Y. Tsai, Ernest T. Hawk
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2016) 9 (2): 125–127.
https://doi.org/10.1158/1940-6207.CAPR-15-0432
Published: 01 February 2016
View articletitled, When “Effective” Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design
Open the PDF for When “Effective” Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design in another window